SB 17 would require health insurers and entities that administer prescription drug coverage, including pharmacy benefit managers, to count third-party payments made on behalf of an enrollee toward that enrollee’s cost-sharing obligations. The bill specifically includes payments from independent charities and similar patient assistance sources, and defines cost-sharing to include copayments, coinsurance, deductibles, and out-of-pocket maximums. It applies to individual and group accident and health insurance policies that cover prescription drugs.
The bill creates an exception for covered prescription drugs that have a generic alternative or an interchangeable biological product, meaning third-party assistance would not have to be applied to cost-sharing in those cases. It also allows insurers or their contracted entities to require disclosure of certain information about assistance payments if the payment is not coordinated at the point of sale, including the enrollee’s name, the drug, the amount paid, and applicable program terms. High deductible health plans and catastrophic plans are exempt until the enrollee meets the federal minimum deductible, to preserve federal tax-advantaged status where necessary.
Impact
If enacted, SB 17 would amend New Hampshire insurance law by adding a new section to RSA 415 and, according to the fiscal note, would also affect related provisions in RSA 420-A and RSA 420-B governing fully insured commercial health plans and pharmacy benefit administration. The practical effect would be to require insurers and PBMs to credit third-party assistance toward deductibles and other out-of-pocket limits, which could reduce direct costs for some patients using expensive medications but may also alter how insurers design benefits and manage drug spending. The fiscal note anticipates indeterminable increases in insurance premiums and, correspondingly, indeterminable increases in insurance premium tax revenue and in costs to counties and local governments that purchase insurance coverage.
Sentiment
The overall tone in the available materials is policy-supportive but cautious. The bill appears aimed at helping patients access prescription drugs by ensuring that outside assistance counts toward their cost-sharing obligations, which is generally a consumer-friendly approach. At the same time, the fiscal analysis from the Insurance Department warns that the bill could disrupt insurer pricing assumptions and push premiums upward, creating uncertainty about the net effect on the market. No committee transcript or recorded vote is provided, so there is no direct evidence of floor or committee debate beyond the agency fiscal commentary.
Contention
The main point of contention is whether third-party assistance, especially manufacturer or charity-funded copay support, should reduce a patient’s out-of-pocket burden or instead be excluded from cost-sharing calculations to preserve insurer cost controls. Opponents or skeptics are likely to focus on premium inflation, actuarial disruption, and the possibility that assistance programs could be used to steer use of higher-cost brand-name drugs. Supporters are likely to emphasize affordability and access for patients facing high drug costs. A secondary issue is the bill’s carveout for generic alternatives and interchangeable biological products, which reflects concern about preserving incentives to use lower-cost substitutes while still allowing assistance for other drugs.
Removing fees and charges for governmental records under the right-to-know law and reinstating potential liability for disclosure of information exempt from disclosure.